Hillevax Inc (HLVX) Peer Comparison

$2.09

$0.00 (0.00%)

As on 17-Sep-2025 09:30EDT

Market cap

$105 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.7

Div. Yield

0 %

Edit

	Hillevax Inc (HLVX)	Y-mAbs Therapeutics (YMAB)
Market cap ($ Mln)	105	391
Revenue ($ Mln)	--	85
Net Profit ($ Mln)	-71.10	-22.22
Net Margin (%)	--	-26.03
RoE (%)	-47.04	-24.76
Price to Earnings	--	--
Price-To-Book	0.71	4.47

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Hillevax Inc (HLVX)	Y-mAbs Therapeutics (YMAB)
Operating Revenue	0.00	85.39
Cost of Revenue	0.00	15.75
Gross Profit	--	72.43
Operating Expenses	77.12	96.23
Operating Profit (EBIT)	-77.12	-26.65
Other Income	0.00	0.00
Profit before Tax	-71.10	-22.62
Provision for Tax	0.00	-0.39
Profit after Tax (Net Income)	-71.10	-22.22
Minority Interest	0.00	0.00
Consolidated Profit	0.00	0.00

Liabilities ($ Mln)

	Hillevax Inc (HLVX)	Y-mAbs Therapeutics (YMAB)
Shareholder's Funds	147.82	87.49
Minority Interest	0.00	0.00
Non-Current Liabilities	20.95	6.77
Current Liabilities	6.15	22.95
Total Liabilities	192.69	119.90

Assets ($ Mln)

	Hillevax Inc (HLVX)	Y-mAbs Therapeutics (YMAB)
Non-Current Assets	12.67	25.42
Current Assets	162.24	91.79
Total Assets	192.69	119.90
Total Debt*	23.54	3.12
Net Current Assets	156.09	68.84

Cashflow ($ Mln)

	Hillevax Inc (HLVX)	Y-mAbs Therapeutics (YMAB)
Cash From Operating Activities	-108.79	-15.71
Cash Flow from Investing Activities	58.40	--
Cash from Financing Activities	-11.82	4.31
Net Cash Inflow / Outflow	--	--

Ratios

Profitability Ratios

	Hillevax Inc (HLVX)	Y-mAbs Therapeutics (YMAB)
ROCE (%)	-59.42	-30.39
ROE (%)	-47.04	-24.76
ROA (%)	-28.04	-13.56
EBIT Margin (%)	--	-24.73
Net Margin (%)	--	-26.03
Cash Profit Margin (%)	--	0.00

Growth Ratios

	Hillevax Inc (HLVX)	Y-mAbs Therapeutics (YMAB)
Revenue Growth (%)	--	-1.34
EBIT Growth (%)	54.85	23.61
Net Profit Growth (%)	54.50	9.71
EPS Growth (%)	57.64	11.92
Book Value Growth (%)	-29.21	-10.85

Valuation Ratios

	Hillevax Inc (HLVX)	Y-mAbs Therapeutics (YMAB)
Price / Earnings	-0.70	-11.84
Price / Book Value	0.66	3.82
Dividend Yield (%)	--	--
EV/EBITDA	0.29	-9.29
Market Cap ($ Cr)	--	--

Solvency Ratios

	Hillevax Inc (HLVX)	Y-mAbs Therapeutics (YMAB)
Debt to Equity	0.00	0.00
Short term debt to equity ratio	0.02	0.01
Current Ratio	26.39	4.00
Quick Ratio	26.39	3.58
Interest Coverage	-37.37	--

Operating Efficiency Ratios

	Hillevax Inc (HLVX)	Y-mAbs Therapeutics (YMAB)
Debtors to sales (%)	--	18.43
Asset Turnover	0.00	0.52
Receivable days	--	87.77
Inventory Days	--	147.04
Payable days	--	152.34
Cash Conversion Cycle	--	82.47

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly